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Available online 21 August 2016West Syndrome is characterized by infantile spasms, a hypsarrhythmic electroencephalogram (EEG) pattern, and
a poor neurodevelopmental prognosis. First-line treatments include adrenocorticotrophic hormone (ACTH) and
vigabatrin, but adverse effects often limit their use. CPP-115 is a high-afﬁnity vigabatrin analogue developed to
increase therapeutic potency and to limit retinal toxicity. Here, we present a child treatedwith CPP-115 through
an investigational newdrugprotocolwho experienced amarked reduction of seizureswith no evidence of retinal
dysfunction. Given the potential consequences of ongoing infantile spasms and the limitations of available
treatments, further assessment of CPP-115 is warranted.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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CPP-1151. Introduction
West Syndrome is an infantile-onset epileptic encephalopathy
characterized by the following: 1) clusters of ﬂexor, extensor, or
mixed spasms (infantile spasms); 2) cognitive and/or psychomotor
disability; and 3) hypsarrhythmia on electroencephalogram (EEG).
West Syndrome can result from diverse genetic and acquired causes,
and inmany cases, the etiology remainsunknown [1,2]. Patients typical-
ly develop spasms in the ﬁrst year of life which often resolve by four
years of age. Spasms are often accompanied or followed byother seizure
types. Further, the combination of the underlying disorder, abundant
interictal epileptiform activity, and seizures often causes severe intellec-
tual and motor deﬁcits [3,4].
Early and effective treatment intervention may reduce or prevent
developmental delays associated with West Syndrome [5,6]. The FDA-
approved treatments are limited by tolerability and efﬁcacy [4]. Adreno-
corticotropic hormone (ACTH) and (RS)-4-aminohex-5-enoic acid
(vigabatrin) are effective in many cases but have potentially serious
adverse effects [3,4]. The ACTH can lead to immunosuppression and in-
fections, hypertension, metabolic abnormalities, and renal impairment
and is rarely fatal [7]. Vigabatrin can cause progressive and potentiallyEpilepsy Center, 223 East 34th
ele).
. This is an open access article underirreversible visual ﬁeld loss from retinal toxicity. Despite the risks
associated with vigabatrin, its efﬁcacy makes it the ﬁrst line treatment
for some etiologies of infantile spasms, especially tuberous sclerosis
[8]. There is a need for safer and more effective therapies.
Vigabatrin inactivates GABA aminotransferase (GABA-AT), an intra-
cellular enzyme that degrades GABA, increasing synaptic GABA concen-
trations [9]. (1S, 3S)-3-amino-4-diﬂuoromethylenyl-1-cyclopentanoic
acid (CPP-115) is a high-afﬁnity vigabatrin analogue. CPP-115 was de-
veloped to produce greater therapeutic potency than vigabatrinwithout
retinal toxicity [10,11]. The molecular structure prevents formation of
the reactive metabolite implicated in retinal toxicity [10]. Mechanism-
based inhibition assays demonstrated that CPP-115 design increased
its ability to inactivate GABA-AT to 187 times that of vigabatrin [11].
Animal studies support increased efﬁcacy and decreased retinal
toxicity associated with CPP-115. Administration of CPP-115 in a
multiple-hit rat model of infantile spasms signiﬁcantly reduced spasms
and normalized the EEG. Results were signiﬁcant at a dose 400 times
lower than that of vigabatrin, with effects lasting two to three times as
long [12]. Rats treated with CPP-115 had reduced retinal toxicity com-
pared with those treated with vigabatrin [13]. In humans treated
with CPP-115 for one week, there were signiﬁcantly increased
GABA concentrations on 1H magnetic resonance spectroscopy
(MRS) in the supplementary motor area and parietal–occipital cor-
tex [14].
The FDA has granted CPP-115 orphan drug designation for the treat-
ment of infantile spasms. The potential safety and efﬁcacy of CPP-115the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in an open-label investigational new drug protocol.2. Case report
The boy presented at one year of age with episodes of head-nodding
and shoulder/arm shrugs upon waking. After an EEG recorded episodic
electrodecremental responses associated with motor paroxysms and
hypsarrhythmia, infantile spasms were diagnosed. Magnetic resonance
imaging (MRI) showed a mild decreased cerebral volume,
dysmeylination, and an atrophic corpus callosum. Genetic testing, in-
cludingwhole exome sequencing of the child and parents,was negative.
The patient also had cortical blindness, bilateral sensory hearing loss,
hypotonia, and global developmental delay. Over the next two years,
spasms continued despite various treatment combinations of ACTH,
clonazepam, zonisamide, vigabatrin, valproic acid, ketogenic diet,
topiramate, clobazam, felbatol, intravenous solumedrol, and lamotrigine.
Seizure cessation was achieved only during the ﬁrst month of treatment
with vigabatrin. An EEG ﬁvemonths prior to CPP-115 initiation recorded
several tonic spasms seizures on one day and 71 parental pushbuttons
within a separate 16-hour period, of which ~50% were myoclonic jerks
without EEG correlates and ~50% were spasms with ictal correlates.
This patient began taking CPP-115 at age 3 years as an FDA-
authorized investigational drug with institutional review board
approval. His current antiseizure drugs were clobazam 1.8 mg/kg daily
and vigabatrin 157.5 mg/kg, and he was on the ketogenic diet.
Vigabatrin was reduced to 118.1 mg/kg with CPP-115 treatment
initiation. CPP-115 is a powder prepared in 5mL of sterilewater and ad-
ministered as a liquid via syringe. It was mixed with a noncarbonated,
artiﬁcially sweetened beverage. CPP-115 titrations followed a dosing
protocol provided by Catalyst Pharmaceutical Partners, the drug manu-
facturer. CPP-115 titrations started at 0.2 mg/kg with planned increases
of 0.2 mg/kg per week as tolerated up to a maximum daily dose of
1.2mg/kg. CPP-115 reachedmaximal dosing in 6 weeks as per protocol.
However, thedosewas reduced to 1.1mg/kg ~2months later because of
concerns over decreased appetite and fatigue, both of which resolved
within 1 year of CPP-115 initiation. His seizure frequency increased
with the reduction of the CPP-115 dose. At the time of the dose reduc-
tion, the patient was also taking 83.3 mg/kg vigabatrin. Vigabatrin was
completely weaned within 1 year of CPP-115 initiation (Fig. 1). Mood
and cognitive improvement were noted with the cessation of
vigabatrin, but an increase in seizure frequency persisted for ~5months.
During the vigabatrin weaning period, CPP-115 was increased byFig. 1. Patient's estimated daily seizure frequency as reported by his pare0.03 mg/kg. Clobazam was also reduced to 0.83 mg/kg daily within
the same year.
The patient's seizure frequency went from ~100 seizures per day
before CPP-115 to ~25–30 seizures per day after 1.5 years on CPP-115
(Fig. 1). The greatest reduction in seizures was reported during the
two months that he was on ~83.3 mg/kg vigabatrin and the maximal
dose of CPP-115 (1.2 mg/kg or 14.4 mg). During this time, his seizures
were initially reduced to 5–10/day, and hewent fourweekswithout ob-
served seizures. After the weaning of the vigabatrin, tiagabine was in-
troduced to control a relative increase in reported seizure frequency
and demonstrated some seizure control, but gagging, insomnia, and de-
creased appetite led to discontinuation of tiagabine. During treatment
with CPP-115, electroretinograms (ERGs), complete blood count, and
comprehensive metabolic panel were obtained every 3–6 months
with no abnormalities. A recent 18-hour, 24-channel EEG study showed
the absence of normalwake and sleep state features, moderate general-
ized slowing, increased beta activity, bilateral multifocal epileptiform
discharges, and generalized discharges. The report noted improvement
because of a complete lack of electrodecremental responses or seizures.
The events classiﬁed as myoclonic seizures by the parents, were milder
in intensity than before CPP-115, and were not associated with EEG
changes. Currently, the patient continues to experience reduced
myoclonic seizures, ~25–30 per day according to parental report, on
CPP-115 at 1.2 mg/kg or 13.9 mg per day, clobazam 0.4 mg/kg daily,
and the ketogenic diet.
Clinically, with the addition of CPP-115, his parents and therapists
observed improved environmental interaction, attention, and motor
function.3. Discussion
This case study suggests sustained efﬁcacy and tolerability of
CPP-115 in treating epileptic spasms. Prior to CPP-115 treatment, this
patient's seizures had failed ten drugs and the ketogenic diet, and this
patient had approximately 100 seizures per day. One year after starting
CPP-115 and tapering off of clobazam and vigabatrin, his reported sei-
zure frequency decreased by more than 50%, and his cognition and be-
havior improved. An 18-hour EEG at age ﬁve revealed resolution of
electrographic seizures and reduction of interictal discharges by more
than 50%. The patient had no evidence of retinal damage seen on regular
ERGs, which is consistent with a potentially increased safety proﬁle
with CPP-115 versus vigabatrin [10,11,13]. The cognitive and behavioral
improvement observed by parents and therapists could have been duents and concurrent vigabatrin (VGB) and CPP-115 dosages (mg/kg).
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other factors.
As an open-label, single subject case report, this evidence is limited
by several factors. The discrepancy between the seizure-free 18-hour
EEG and parental report of 25–30 seizures per day suggests some inaccu-
racies in parental reporting of seizure frequency. Many of his ‘myoclonic
seizures’may be nonepileptic or seizures that are not associated with an
EEG change. Notably, the baseline parental reports of ~100 seizures per
day were associated with N35 electrographic seizures per day on an
EEG, and an additional equal number of events reported by the family
weremyoclonic jerks lacking ictal correlates. Parental reports of reduced
seizure frequency and duration were concordant with the improvement
observed in the EEG. While the reduction in reported seizure frequency
and improvement in EEG could represent the natural clinical progression
of his disorder, his seizure frequency had remained constant except for a
one-month cessation during initial vigabatrin therapy. Despite ten anti-
epileptic drugs and dietary therapy, his seizures remained drug-resis-
tant. Another limitation was that CPP-115 was not administered in a
blinded setting but in tandem with other antiseizure medications. The
patient was treated simultaneously with vigabatrin during the ﬁrst
year of treatment, during which time the therapy exhibited the most
marked apparent reduction in seizure frequency. This could reﬂect a syn-
ergistic effect that warrants further investigation. However, vigabatrin
was weaned and has not been reinitiated in the last year, during which
time the patient has continued to have improved seizure control. Finally,
we cannot exclude long-term retinal toxicity in this child. Never the less,
regular ERGs are considered sensitive to detect vigabatrin-associated ret-
inal toxicity and meet current clinical safety guidelines to detect retinal
dysfunction in infants and other patients who cannot perform perimetry
[15].
4. Conclusion
Despite the appreciable limitations of the available data, the reported
reduction in seizure frequency and documented improvements in the
interictal and ictal EEG temporally associated with CPP-115 initiation in
this patient are noteworthy. In the context of infantile spasms and asso-
ciated morbidity, mortality, and poor neurodevelopmental outcomes,
CPP-115 presents a promising alternative to vigabatrin therapy, albeit
one requiring further comprehensive analysis in a controlled setting.Conﬂict of interest
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